DiaGenic's tests are based on the observation that a focal lesion or disorder gives rise to a systemic response which can be measured in the blood. This response can be detected by measuring the amount of RNA for selected genes in peripheral blood using gene expression technology.

DiaGenic's concept can be further developed for use in the diagnosis of many serious diseases. Based on commercial potential and medical needs DiaGenic's main focus has been on the development of products for the early diagnosis of Alzheimer's Disease.